Merck & CoNYSE: MRK

On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.

The upcoming years could be challenging for the big pharmaceutical company, but the future seems more promising.

The Merck & Co., Inc. Q3 2024 Earnings Call is scheduled for October 31, 2024, at 09:00 AM ET. Key company participants include Peter Dannenbaum, Rob Davis, Caroline Litchfield, and Dean Li. Various conference call participants from different financial institutions will also be present.

Merck (MRK) reported quarterly earnings of $1.57 per share, which is higher than the Zacks Consensus Estimate of $1.50 per share. This is a decrease compared to earnings of $2.13 per share from the same period last year.

Merck & Co Inc (NYSE:MRK, ETR:6MK) exceeded expectations for the third quarter, even though sales of its Gardasil vaccine, diabetes medications, and Covid-19 treatment were lower. The company announced that its revenue for the three months ending in September rose by 4% to $16.66 billion, surpassing the market's forecast of $16.46 billion.

Becky Quick from CNBC shares the company's earnings results for the quarter.

Merck's stock fluctuated between rising and falling in the premarket trading.

On Thursday, Merck & Co announced that its third-quarter earnings were better than anticipated, thanks to strong sales of its popular cancer drug Keytruda. However, the U.S. pharmaceutical company also noted a second consecutive quarter of low demand for its Gardasil vaccine in China.

Merck announced that its revenue and adjusted earnings for the third quarter exceeded expectations. The company experienced robust sales from its leading cancer medication, Keytruda, as well as from newly launched treatments and its animal health division.